European Association for the Study of Diabetes (EASD)

New Capabilities

As of October 2026: Hosted the annual meeting where olatorepatide data were presented

Hansoh Pharma presented full Phase III results for olatorepatide at the European Association for the Study of Diabetes meeting in Milan on October 2. Overweight and obese patients on the highest 15 mg dose lost 19.3% of their body weight on average by week 48, and the weight-loss curve had not flattened.

Updated Oct 2